Cocrystal Pharma Reports Results From Single-Ascending Dose Cohorts Of Phase 1 Study With CDI-988, Its Oral Pan-Viral Norovirus/Coronavirus Protease Inhibitor

Cocrystal Pharma, Inc. (NASDAQ:COCP) ("Cocrystal" or the "Company") today reported favorable safety and tolerability results from the single-ascending dose (SAD) cohorts of the Phase 1 study in healthy volunteers with CDI-988, its potent, oral, pan-viral protease inhibitor. CDI-988 was specifically designed and developed using Cocrystal's proprietary structure-based drug discovery platform technology as a broad-spectrum antiviral inhibitor to a highly conserved region in the active site of 3CL viral proteases. It is being developed as the first dual, broad-spectrum antiviral for the treatment of norovirus and coronaviruses.